The Translational Genomics Research Institute

Mayo Foundation for Medical Education and Research

Queensland University of Technolgy

Sara Byron

Michael Richard Barrett

George Vasmatzis

David Craig

Mitesh J Borad

John Carpten

Keith Stewart

Alan Bryce

Jessica Aldrich

Pamela Pollock

Various embodiments provide compositions and methods for detecting cancers containing an NRG1 fusion event and treating a patient with a therapeutic agent that is targeted to the NRG1 fusion. Exemplary compositions for treating cancers containing the NRG1 fusion may comprise therapeutic agents inhibiting Epidermal Growth Factor Receptor and/or ERBB2 such as cetuximab, panitumumab, Sym004, MM-151, mAb 806, mAb 528, MEHD794A, gefitinib, erlotinib, lapatinib, afatinib, PD153035, AG1478, trastuzumab, and pertuzumab. In some embodiments, the therapeutic agent may be a combination of trastuzumab, and pertuzumab.

Targeted therapies for cancer

This disclosure provides tyrosine kinase protein and nucleic acid variants, particularly FGFR2 variants, which are linked to drug resistance. The disclosure further provides methods of diagnosis and theranosis, and development of new therapeutic agents using these molecules and fragments thereof, and kits for employing these methods and compositions.

Methods of determining susceptibility of tumors to tyrosine kinase inhibitors

Growing community of inventors

Phoenix, AZ, United States of America

Sara Byron